 |
VasoMedical Selected to Speak about EECP® Therapy at FIME 2013 |
Larry Liebman to Present on Patient Outcomes Resulting from Treatment with Enhanced External Counterpulsation (EECP®) Therapy
July 23, 2013 - WESTBURY, N.Y. - To continue the effort to spread awareness about the benefits of EECP® Therapy for treating heart disease, VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® Therapy systems, the gold standard of ECP therapy, has been selected to present at the 2013 Florida International Medical Exposition (FIME) on August 7, 2013 in Miami Beach, FL.
FIME is the second most important medical trade fair and congress for the Latin American market and is one of the largest international medical trade shows held annually in the United States. The exposition draws nearly 50,000 attendees from conventional distribution and sales channels, group purchasing organizations, integrated delivery networks, hospitals, imaging centers, private practice facilities and home medical equipment/durable medical equipment providers. In addition to an expansive exhibitor representation of more than 1,400 companies, FIME 2013 also includes focused seminars that will stimulate critical thinking, challenge current healthcare programs, and provide innovative, cutting edge insights.
Larry Liebman, Vice President of Sales and Marketing for VasoMedical, will give a presentation titled “Enhanced External Counterpulsation (EECP®) Improves Patients Outcomes” at 11:00am ET on Wednesday, August 7 in Room D234 of the Miami Beach Convention Center. His presentation is part of the Clinicon section of the symposia, which is designed to showcase the cost efficiency and outcomes of new and innovative technologies and therapeutics.
“My presentation on patient outcomes of treatment with Enhanced External Counterpulsation Therapy will introduce and explain how this non-invasive treatment works to reduce or eliminate the symptoms of cardiovascular disease while simultaneously significantly improving patients' quality of life and reducing emergency room visits and hospitalization,” stated Mr. Liebman. “Currently, when medication fails, the approach to managing ischemic heart disease is to quickly turn to invasive procedures such as surgery or stenting, but that's not always the best answer. With a greater awareness of EECP® Therapy and an appreciation for its proven clinical and financial outcomes, more physicians will refer patients to this treatment modality and more patients will ask for it to treat their disease without the risks and costs associated with invasive procedures.”
EECP® Therapy is an FDA-cleared non-invasive outpatient treatment that increases blood flow and reduces the workload of the heart to treat heart conditions such as angina and congestive heart failure. Published clinical studies have shown that EECP® Therapy reduces arterial stiffness, improves cardiovascular health and has a significant effect on improving patient quality of life. The Therapy is covered by Medicare and most private insurance companies for the treatment of refractory angina.
Mr. Liebman continued, “presenting at FIME 2013 will certainly increase discussions about applications of EECP® Therapy in the U.S. as well as Latin American countries. The information and scientific evidence I will share during this presentation will educate medical and healthcare professionals about the value of EECP® Therapy – both in terms of financial impact on the healthcare system as well as patient wellness. FIME is an excellent forum to inform and educate attendees from the U.S., Mexico, Central America and South America about the life changing medical advance that EECP® Therapy represents.”
For more information about VasoMedical, visit the Company's website at www.vasomedical.com.
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
212-896-1216 / 212-896-1220
lgoldberg@kcsa.com / swolf@kcsa.com